Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

iming, design, enrollment and cost of clinical trials; unexpected delays in clinical trials and preparation of materials for submission to the FDA as part of our NDA filing; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2006 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, Inc., +1-415-225-5050, forPharmacyclics, Inc.

Web site: http://www.pharmacyclics.com/

Ticker Symbol: (NASDAQ-NMS:PCYC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/1/2015)... 1, 2015 Sleep Specialists, LLC a ... HGE Health Care Solutions, a leader in digital ... comprehensive sleep management and cost reduction program for ... OSA is a chronic medical condition characterized by ... increase a patient,s risk for cardiovascular disease, hypertension, ...
(Date:9/1/2015)... LLC , a leading distributor of advanced medical imaging equipment based ... been awarded exclusive rights to represent the complete Shimadzu Medical Systems ... Alpha Imaging,s existing Shimadzu sales and service responsibilities with those in ... Indiana , Pennsylvania , Kentucky ... , Delaware and Virginia ...
(Date:9/1/2015)... Sept. 1, 2015  Results from an interim analysis ... that 5g of idarucizumab enabled emergency surgery to ... treated with dabigatran (Pradaxa ® dabigatran etexilate ... effect of dabigatran enabled patients to be urgently ... of 1.7 hours between administration of idarucizumab and ...
Breaking Medicine Technology:Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Alpha Imaging Expands Shimadzu Territory 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
... Cobalis Corp. (OTC,BB: CLSC), a pharmaceutical development ... has been informed by,its independent contract research ... combine Cobalis' three locked data bases into ... statistical analysis,required to generate top-line results for ...
... evidence,increasingly links arterial calcification to the presence ... scientists question,whether a nanoparticle can live and, ... disease. , ,A new Mayo Clinic study ... plaque-filled arteries in animal models. The,study suggests ...
Cached Medicine Technology:Cobalis Expects to Report Phase III Top-Line Results in May 2Evidence of Nanoparticles Found in Plaque-Filled Arteries 2
(Date:9/2/2015)... ... September 02, 2015 , ... Every year at this time, students prepare to ... are prepared to face the academic workload confronting them. They just don’t have the ... since schools don’t teach students how to study. , “Bankers bank. Salesmen sell. Teachers ...
(Date:9/2/2015)... ... September 02, 2015 , ... The 2015 China ... international investment and business conference will be hosted at five star Beijing Kunlun ... full-weekend networking conference will feature leading EB-5 industry professionals and Chinese private equity ...
(Date:9/2/2015)... ... September 02, 2015 , ... A recent survey by Consumer Reports ( http://bit.ly/1h67tL8 ... its negative impact on consumers. It was reported that 33% are paying an average ... much as an extra $100 compared to last year. Among the drugs that saw ...
(Date:9/2/2015)... ... September 02, 2015 , ... Amada Senior Care, premier provider of in-home care ... Johnson County location. Amada franchise partners Mike and Mell Fleming came to ... and spent over 20 years in medical device sales while Mell spent over 30 ...
(Date:9/2/2015)... Chicago, IL (PRWEB) , ... September 02, 2015 ... ... engineer of patented products, announces Hand Free Pocket Cop, a safety invention that ... in the US is worth $31 billion," says Scott Cooper, CEO and Creative ...
Breaking Medicine News(10 mins):Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7
... that polymerase chain reaction (PCR) testing for Borrelia burgdorferi ... may confirm the diagnosis of Lyme arthritis, but is ... patients whose arthritis persists after antibiotic therapy. Findings of ... , a journal of the American College of Rheumatology ...
... DENVER According to a new study conducted by researchers ... pulmonary disease (COPD) an effective workout and one that, ... "Our study showed that COPD patients exercised at ... five minutes of specified Wii Fitexercises, indicating the Wii Fit ...
... , MONDAY, May 16 (HealthDay News) -- A chemical ... may pose a health risk, a new study indicates. ... at levels of the chemical, isocyanic acid, in the ... chemical with conventional measurement techniques, explained the U.S. National ...
... , MONDAY, May 16 (HealthDay News) -- Asthma patients ... flares can suffer worse outcomes, including hospitalization. That,s ... patients in two New York City emergency departments. They ... and their attempts at self-management before they decided to ...
... Randy Dotinga HealthDay Reporter , MONDAY, May 16 (HealthDay ... infested by parasites despite clinical evidence to the contrary. Now, ... in the patient,s head -- is often right on target. ... bugs, worms or germs had invaded their skin. In all but ...
... an explanation of how stroke patients can achieve better recovery. ... has proved to benefit recovery during the later phases of ... a hormone that is found in the blood and contributes ... of this hormone are higher in people who exercise regularly ...
Cached Medicine News:Health News:Deer tick bacteria DNA in joint fluid not reliable marker of active lyme arthritis 2Health News:Deer tick bacteria DNA in joint fluid not reliable marker of active lyme arthritis 3Health News:COPD patients may breathe easier, thanks to the Wii 2Health News:COPD patients may breathe easier, thanks to the Wii 3Health News:Chemical in Smoke May Pose Health Risk 2Health News:Don't Delay Emergency Care When Asthma Flare-Ups Strike 2Health News:For Some, Bugs Crawling on Skin Is a Delusion 2Health News:Hormone improves long-term recovery from stroke 2
... AIA-1800 is the newest and most advanced ... The AIA-1800 launches with a full ... markers, thyroid, reproductive, cardiac, and anemia assays. ... throughput, bar-coded primary tube sampling, auto dilution, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... of Vision and Contrast Sensitivity. The ... and glare luminance levels for accurate ... with/without glare and background luminance Comply ... standards. All Light Levels Microprocessor Controlled ...
Medicine Products: